JP2003520246A5 - - Google Patents

Download PDF

Info

Publication number
JP2003520246A5
JP2003520246A5 JP2001552925A JP2001552925A JP2003520246A5 JP 2003520246 A5 JP2003520246 A5 JP 2003520246A5 JP 2001552925 A JP2001552925 A JP 2001552925A JP 2001552925 A JP2001552925 A JP 2001552925A JP 2003520246 A5 JP2003520246 A5 JP 2003520246A5
Authority
JP
Japan
Prior art keywords
use according
cop1
medicament
cns
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001552925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003520246A (ja
JP4328050B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/002117 external-priority patent/WO2001052878A2/en
Publication of JP2003520246A publication Critical patent/JP2003520246A/ja
Publication of JP2003520246A5 publication Critical patent/JP2003520246A5/ja
Application granted granted Critical
Publication of JP4328050B2 publication Critical patent/JP4328050B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001552925A 2000-01-20 2001-01-22 神経保護療法のためのコポリマー1、関連ペプチド及びポリペプチドならびにそれらによって処理されたt細胞の使用 Expired - Fee Related JP4328050B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US48779300A 2000-01-20 2000-01-20
US09/487,793 2000-01-20
US20979900P 2000-06-07 2000-06-07
US06/209,799 2000-06-07
US62021600A 2000-07-20 2000-07-20
US09/620,216 2000-07-20
PCT/US2001/002117 WO2001052878A2 (en) 2000-01-20 2001-01-22 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Publications (3)

Publication Number Publication Date
JP2003520246A JP2003520246A (ja) 2003-07-02
JP2003520246A5 true JP2003520246A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4328050B2 JP4328050B2 (ja) 2009-09-09

Family

ID=27395416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001552925A Expired - Fee Related JP4328050B2 (ja) 2000-01-20 2001-01-22 神経保護療法のためのコポリマー1、関連ペプチド及びポリペプチドならびにそれらによって処理されたt細胞の使用

Country Status (16)

Country Link
US (2) US6844314B2 (cg-RX-API-DMAC7.html)
EP (1) EP1248643B1 (cg-RX-API-DMAC7.html)
JP (1) JP4328050B2 (cg-RX-API-DMAC7.html)
KR (1) KR100822695B1 (cg-RX-API-DMAC7.html)
CN (1) CN100360180C (cg-RX-API-DMAC7.html)
AT (1) ATE302020T1 (cg-RX-API-DMAC7.html)
AU (1) AU780188B2 (cg-RX-API-DMAC7.html)
CA (1) CA2397785C (cg-RX-API-DMAC7.html)
DE (1) DE60112718T2 (cg-RX-API-DMAC7.html)
DK (1) DK1248643T3 (cg-RX-API-DMAC7.html)
ES (1) ES2243450T3 (cg-RX-API-DMAC7.html)
HK (1) HK1054507B (cg-RX-API-DMAC7.html)
IL (2) IL150800A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007106A (cg-RX-API-DMAC7.html)
PT (1) PT1248643E (cg-RX-API-DMAC7.html)
WO (1) WO2001052878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US7351686B2 (en) * 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
WO2004060265A2 (en) 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20070197424A1 (en) * 2003-09-16 2007-08-23 Friedman Scott L Glatiramer acetate for use as an immuno-modulatory agent
CA2546077C (en) * 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
RU2006134701A (ru) * 2004-03-01 2008-04-10 Пептиммьюн Способы и композиции для лечения аутоиммунных заболеваний
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
CA2565819A1 (en) 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
WO2006016156A1 (en) * 2004-08-10 2006-02-16 1...Limited Non-planar transducer arrays
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
DK1799703T3 (da) * 2004-09-09 2010-04-19 Teva Pharma Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
RS52867B (sr) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン,インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
JP5412280B2 (ja) * 2006-06-28 2014-02-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 加齢性黄斑変性症の治療法
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (es) * 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2545381A1 (en) * 2010-03-10 2013-01-16 Yeda Research And Development Co. Ltd. Cellular blood markers for early diagnosis of als and for als progression
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
JP6149831B2 (ja) * 2014-09-04 2017-06-21 信越化学工業株式会社 シリコーン組成物
WO2017077539A1 (en) 2015-11-03 2017-05-11 Ariel-University Research And Development Company Ltd. Compositions for regeneration and repair of neural tissue
US11058720B2 (en) * 2016-05-20 2021-07-13 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
JP7123932B2 (ja) * 2016-09-02 2022-08-23 クリストファー ジェイ. ソアレス 神経保護及び神経疾患におけるcgrp受容体アンタゴニストの使用
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis with adipose-derived stem cells
CN114790475B (zh) * 2021-01-25 2025-01-10 首都医科大学附属北京天坛医院 一种与亨廷顿病相关的肠道微生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2002503658A (ja) * 1998-02-13 2002-02-05 オートイミューン インク COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途

Similar Documents

Publication Publication Date Title
JP2004507460A5 (cg-RX-API-DMAC7.html)
CN100438906C (zh) 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
EP2327712A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
JP2006506942A5 (cg-RX-API-DMAC7.html)
WO1999060021A3 (en) Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
JP2010505482A5 (cg-RX-API-DMAC7.html)
DK1248643T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
JP2010516290A5 (cg-RX-API-DMAC7.html)
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
JP2003518507A5 (cg-RX-API-DMAC7.html)
ES2541780T3 (es) Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
RU2013112616A (ru) Пептид cdca1 и включающее его фармацевтическое средство
JP2008530975A5 (cg-RX-API-DMAC7.html)
CA2411786A1 (en) A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2000075173A3 (en) Peptide fragments of colostrinin
JP2009542622A5 (cg-RX-API-DMAC7.html)
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2003105750A3 (en) ANTIGEN PRESENTER CELLS FOR NEUROPROTECTION AND NERVOUS REGENERATION
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
JP2005512518A5 (cg-RX-API-DMAC7.html)
RU2011130796A (ru) Пептиды c1orf59 и содержащие их вакцины
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
ES2732669T3 (es) Tratamiento de la esclerosis múltiple
RU2012100241A (ru) Лечение хориоидальной неоваскуляризации с помощью вакцин